Kenneth C. Frazier - Nov 7, 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
Executive Chair, Director
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Kenneth C. Frazier
Stock symbol
MRK
Transactions as of
Nov 7, 2022
Transactions value $
-$23,471,433
Form type
4
Date filed
11/8/2022, 03:56 PM
Previous filing
Nov 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $0 +236K +33.65% $0.00 936K Nov 7, 2022 Direct
transaction MRK Common Stock Sale -$2.45M -24.9K -2.66% $98.45 912K Nov 7, 2022 Direct F1
transaction MRK Common Stock Sale -$12.5M -126K -13.84% $99.42 785K Nov 7, 2022 Direct F2
transaction MRK Common Stock Sale -$8.48M -84.7K -10.79% $100.07 701K Nov 7, 2022 Direct F3, F4
holding MRK Common Stock - 401(k) Plan 4.48K Nov 7, 2022 By 401(k) F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -236K -100% $0.00* 0 Nov 7, 2022 Common Stock 236K $53.06 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4 Holdings include shares acquired in dividend reinvestment transactions.
F5 Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
F6 The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.